In Vitro Reaction Phenotyping and Projection of Drug Interactions Mediated by Cytochrome P450 Enzymes for Central Nervous System Drugs as Victims: Implications for Safety in Vulnerable Populations
Drug Metabolism and Disposition · 2026-05 · 54 (5) · 100295
DOI: 10.1016/j.dmd.2026.100295 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Metabolism and Disposition, 2026-05. Verfasst von Veera Raghava Chowdary Palacharla und 6 weiteren Autor:innen. Beteiligte Einrichtung: Drug Discovery and Development, Suven Life Sciences Limited, Hyderabad, India; Department of Pharmacology, Manipal College of Pharmaceutical Sciences…. Hauptthemen laut MEDLINE: Cytochrome P-450 Enzyme System, Central Nervous System Agents. Die Arbeit nennt 80 Literaturangaben.
Abstract (Originalsprache)
Accurate prediction of cytochrome P450-mediated victim drug-drug interactions (DDIs) is critical for the safe use of central nervous system (CNS) drugs, particularly in populations at high risk of polypharmacy. This study evaluated the utility and limitations of in vitro human liver microsomal data for predicting victim DDIs of CNS compounds metabolized by CYP1A2, CYP2B6, CYP2D6, and CYP3A4. Reaction phenotyping with isoform-selective inhibitors quantified the fractional metabolic contribution (fm,cyp) of each enzyme, and inhibition parameters for fluvoxamine (CYP1A2), ticlopidine (CYP2B6), cinacalcet/paroxetine (CYP2D6), and ketoconazole (CYP3A4) were incorporated into a mechanistic static model using unbound hepatic inlet concentrations as surrogates for site of inhibition exposure. Predictions for CYP2B6-, CYP2D6-, and CYP3A4-mediated interactions were generally within 3-fold of observed clinical values. In contrast, CYP1A2 substrates showed high sensitivity to fm,cyp values exceeding 0.9, resulting in underprediction (eg, ramelteon-fluvoxamine, 66-fold) or overprediction (eg, tacrine). Contributing factors may include incomplete characterization of minor metabolic pathways, hepatic accumulation of inhibitors, and limitations of static modeling assumptions. Overprediction of select CYP3A4 interactions, such as lurasidone-ketoconazole, likely reflects underestimation of the fraction escaping intestinal metabolism. These findings indicate that human liver microsome-based reaction phenotyping provides valuable guidance for early DDI risk assessment, particularly for CYP2B6, CYP2D6, and CYP3A4 substrates, but small deviations in fm,cyp for CYP1A2 substrates can lead to substantial underestimation of clinical risk. Integration with physiologically based pharmacokinetic modeling and refined fm,cyp estimates may enhance prediction accuracy and better inform safe CNS drug use, especially in populations prone to polypharmacy. SIGNIFICANCE STATEMENT: Accurate prediction of P450-mediated drug-drug interactions is essential for safe central nervous system drug therapy, especially in patients at high risk of polypharmacy. This study shows that human liver microsome-based reaction phenotyping reliably predicts CYP2B6, CYP2D6, and CYP3A4 interactions, whereas small deviations in fm,cyp for CYP1A2 substrates can cause substantial under- or overprediction. Incorporating physiologically based pharmacokinetic modeling and refined fm,cyp estimates can enhance drug-drug interaction risk assessment and guide safer coadministration of central nervous system-active drugs with potent P450 inhibitors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Drug Discovery and Development, Suven Life Sciences Limited, Hyderabad, India; Department of Pharmacology, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal, Karnataka, India.
- Drug Discovery and Development, Suven Life Sciences Limited, Hyderabad, India. Electronic address: nvsrk@suven.com.
- Department of Pharmacology, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal, Karnataka, India; Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Edu…
- Drug Discovery and Development, Suven Life Sciences Limited, Hyderabad, India.
- Department of Pharmacology, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal, Karnataka, India.
Zitieren
APA
Palacharla, V. R. C., Nirogi, R., Kumar, N., Jayarajan, P., Pantangi, H. R., Petlu, S., & Nandakumar, K. (2026). In Vitro Reaction Phenotyping and Projection of Drug Interactions Mediated by Cytochrome P450 Enzymes for Central Nervous System Drugs as Victims: Implications for Safety in Vulnerable Populations. Drug Metabolism and Disposition, 54(5), 100295. https://doi.org/10.1016/j.dmd.2026.100295
Vancouver
Palacharla VRC, Nirogi R, Kumar N, Jayarajan P, Pantangi HR, Petlu S, et al. In Vitro Reaction Phenotyping and Projection of Drug Interactions Mediated by Cytochrome P450 Enzymes for Central Nervous System Drugs as Victims: Implications for Safety in Vulnerable Populations. Drug Metabolism and Disposition. 2026;54(5):100295. doi:10.1016/j.dmd.2026.100295
BibTeX
@article{Palacharla2026,
author = {Palacharla, Veera Raghava Chowdary and Nirogi, Ramakrishna and Kumar, Nitesh and Jayarajan, Pradeep and Pantangi, Hanumanth Rao and Petlu, Surendra and Nandakumar, Krishnadas},
title = {In Vitro Reaction Phenotyping and Projection of Drug Interactions Mediated by Cytochrome P450 Enzymes for Central Nervous System Drugs as Victims: Implications for Safety in Vulnerable Populations},
journal = {Drug Metabolism and Disposition},
year = {2026},
volume = {54},
number = {5},
pages = {100295},
doi = {10.1016/j.dmd.2026.100295}
}
EUVIMED